Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to $173905.0.

  • HCW Biologics' Depreciation & Amortization (CF) rose 3538.84% to $173905.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 10186.42%. This contributed to the annual value of $1.2 million for FY2024, which is 433.45% up from last year.
  • According to the latest figures from Q3 2025, HCW Biologics' Depreciation & Amortization (CF) is $173905.0, which was up 3538.84% from $291916.0 recorded in Q2 2025.
  • HCW Biologics' Depreciation & Amortization (CF)'s 5-year high stood at $682507.0 during Q4 2024, with a 5-year trough of $107463.0 in Q4 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $173905.0 (2025), whereas its average is $235045.1.
  • Examining YoY changes over the last 5 years, HCW Biologics' Depreciation & Amortization (CF) showed a top increase of 14859.11% in 2024 and a maximum decrease of 5430.29% in 2024.
  • Over the past 5 years, HCW Biologics' Depreciation & Amortization (CF) (Quarter) stood at $107463.0 in 2021, then surged by 143.02% to $261158.0 in 2022, then increased by 5.13% to $274550.0 in 2023, then surged by 148.59% to $682507.0 in 2024, then plummeted by 74.52% to $173905.0 in 2025.
  • Its last three reported values are $173905.0 in Q3 2025, $291916.0 for Q2 2025, and $419010.0 during Q1 2025.